Registration Dossier

Diss Factsheets

Administrative data

Description of key information

In a fixed dose procedure 5 female rats received a single dose of 2000 mg/kg bw by gavage. Rats were observed for 14 days thereafter. No mortality occurred. One female showed hunched posture, ataxia, noisy respiration, increased salivation and lethargy during the first day. The other females showed hunched posture during the first 2 hours after dosing. There were no effects on body weight and no macroscopic findings. Based on these findings the oral LD50 of the substance is > 2000 mg/kg bw.

As the substance is of low acute oral toxicity, is not classified as STOT SE and there are no other signs of systemic toxicity, the acute dermal toxicity study has been waived. As the inhalation exposure route is not relevant for this substance no acute study via the inhalation route is included.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
06 November 2017 to 27 November 2017
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
Qualifier:
according to guideline
Guideline:
EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
GLP compliance:
yes (incl. QA statement)
Test type:
fixed dose procedure
Limit test:
yes
Species:
rat
Strain:
Wistar
Sex:
female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Envigo RMS (UK) Limited, Oxon, UK
- Strain: RccHan™:WIST
- Females (if applicable) nulliparous and non-pregnant:yes
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 164-188 g
- Fasting period before study: overnight before dosing and 3-4 hours after dosing
- Housing: solid-floor polypropylene cages furnished with woodflakes (maximum 4/cage)
- Diet: 2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK ad libitum
- Water: ad libitum
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25 °C
- Humidity (%): 30-70%
- Air changes (per hr): at least 15/hour
- Photoperiod (hrs dark / hrs light): 12/12

Route of administration:
oral: gavage
Vehicle:
DMSO
Details on oral exposure:
VEHICLE
- Concentration in vehicle: 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw
- Justification for choice of vehicle: solubility, substance was not soluble in water or arachis oil

MAXIMUM DOSE VOLUME APPLIED: 10 mL

Doses:
2000 mg/kg bw 1 female
2000 mg/kg bw 4 additional females
No. of animals per sex per dose:
5 females
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
mortality: twice daily (once in weekends)
clinical signs: 30 minutes, 1, 2, and 4 hours after dosing and then daily for up to 14 days
bodyweight: day 0, 7 and 14
- Necropsy of survivors performed: yes
Statistics:
NA
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Mortality:
none
Clinical signs:
in the first female on day 1: hunched posture, ataxia, noisy respiration, increased salivation and lethargy
other females: during first 2 hours after dosing: hunched posture
Body weight:
within normal ranges
Gross pathology:
no abnormalities observed
Interpretation of results:
GHS criteria not met
Conclusions:
The oral LD50 of the substance is > 2000 mg/kg bw
Executive summary:

In a fixed dose procedure 5 female rats received a single dose of 2000 mg/kg bw by gavage. Rats were observed for 14 days thereafter. No mortality occurred. One female showed hunched posture, ataxia, noisy respiration, increased salivation and lethargy during the first day. The other females showed hunched posture during the first 2 hours after dosing. There were no effects on body weight and no macroscopic findings. Based on these findings the oral LD50 of the substance is > 2000 mg/kg bw.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

As the substance is of low acute oral toxicity, is not classified as STOT SE and there are no other signs of systemic toxicity, the acute dermal toxicity study has been waived. As the inhalation exposure route is not relevant for this substance no acute study via the inhalation route is included.

Justification for classification or non-classification

Based on the available information no classification for acute toxicity is necessary according to Regulation (EC) No 1272/2008 (CLP).